Membership

Our members receive our quarterly e-newsletter with members-only content including interviews with dermatologists, information on contests and draws, and are the first to hear about upcoming events.

Membership is free.

Learn More

Biologics and Biosimilars

Biologics are the newest group of drugs approved for the treatment of moderate-to-severe psoriasis. These drugs are given by intravenous infusion or by injection under the skin (subcutaneous injection), and are usually prescribed to patients who have moderate-to-severe psoriasis who have failed or had adverse reactions to systemic therapy or an inadequate response to systemic therapy.  Some of these treatments are also effective in patients who also have psoriatic arthritis. Biologics work by blocking interactions between certain immune system cells and inflammatory pathways that are responsible for the signs and symptoms of psoriasis and psoriatic arthritis. Though these medications target only parts of the immune system, they can increase your susceptibility to an infection. If you are taking one of these medications, it is important that you be followed regularly by a dermatologist, rheumatologist or a physician who has expertise in the use of these medications.  

Biosimilars are biologic medications that are similar, but not identical, to an existing biologic drug. Marketed biosimilars have been demonstrated to be highly similar to a biologic drug that was already authorized for sale (known as the reference biologic drug). Biosimilars, however, are not the same as generic drugs. Generic drugs are small molecules that are chemically synthesized and are molecularly identical to their brand name reference products. Due to the size, complexity, and natural variability of biologic drugs, a biosimilar can be shown to be similar, but not identical to its reference biologic drug. A biosimilar is typically less expensive than its reference biologic product, and may be a suitable alternative for many patients. For more information visit Health Canada Biosimilar Biologic Drugs.

For people enrolled in public drug plans for some specific biologics, certain provinces have initiated new policies which would have people change from a biologic originator drug to its approved biosimilar, with some exceptions.

For more information visit:

British Columbia:  https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/what-we-cover/drug-coverage/biosimilars-initiative-patients

Alberta:  https://www.ab.bluecross.ca/government-plan/biosimilar-initiative.php

New Brunswick:  https://www2.gnb.ca/content/gnb/en/departments/health/MedicarePrescriptionDrugPlan/NBDrugPlan/biosimilars.html

 

 

List of Biologics and Biosimilars (Psoriasis)

Click on a medication for additional information.

List of Biologics and Biosimilars (Psoriatic Arthritis)

Click on a medication for additional information.

How Biologics Work

The immune system is made up of many different parts. Biologics work by targeting specific parts of the immune system to decrease the body’s inflammatory response. They interfere with the immune system’s ability to communicate between certain types of cells by blocking specific protein(s).  Simply put, each class of biologics target a different part, or pathway, to decrease inflammation, reduce pain, and improve function. Currently, there are several different classes of biologics that target different pathways: TNF blockers, IL 17 blockers, IL 12/23 blockers, and IL 23 blockers. If one biologic does not work, or loses its efficacy, another biologic within the same class, or within a different class, may prove to be effective.

 

Etanercept (TNF Blocker)

How Does It Work?

Etanercept is a biologic that targets the overactive immune system in psoriasis. Etanercept works by supressing tumor necrosis factor-alpha (TNFa). Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Etanercept is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
50 mg twice weekly for 3 months, then 50 mg once weekly thereafter

For psoriatic arthritis: 
50 mg once weekly

What Are The Possible Side Effects?

The most common side effects of etanercept include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of etanercept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on etanercept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on etanercept.

Etanercept and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Etanercept should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Etanercept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with etanercept include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with etanercept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/ANo – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar etanercept will be considered on an exceptional case-by-case basis.  
AlbertaBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. All new S/A requests for the treatment of adult Plaque Psoriasis for etanercept-naive patients will be assessed for coverage with Brenzys or Erelzi. Enbrel will not be approved for new etanercept starts for patients with Plaque Psoriasis; however, it is possible that coverage for Enbrel will continue for patients who are currently well maintained on Enbrel in some cases. No 
SaskatchewanBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation 
ManitobaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. Erelzi will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis. Patients will not be permitted to switch from Enbrel to another etanercept product or vice versa, if previously trialed and deemed unresponsive to therapy .Yes – EDS. Erelzi will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis. Patients will not be permitted to switch from Enbrel to another etanercept product or vice versa, if previously trialed and deemed unresponsive to therapy .
OntarioBiologics and BiosimilarsEtanerceptEnbrel®Yes – L/UNo 
QuebecBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
New BrunswickBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/A. New requests for psoriatic arthritis will be processed for the biosimilar versions of etanercept only.
Nova ScotiaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDSYes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after January 1, 2020, a biosimilar will be the product that is approved.  
Prince Edward IslandBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. Yes –S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. 
NunavutBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
YukonBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A; all new etanercept patients will be covered for Brenzys or ErelziYes – S/A; all new etanercept patients will be covered for Erelzi 
British ColumbiaBiologics and BiosimilarsEtanerceptErelzi™No Yes – S/A
AlbertaBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
SaskatchewanBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS  Yes – EDS
OntarioBiologics and BiosimilarsEtanerceptErelzi™Yes – L/U Yes – L/U
QuebecBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A 
New BrunswickBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
Nova ScotiaBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsEtanerceptErelzi™NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
NunavutBiologics and BiosimilarsEtanerceptErelzi™NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptErelzi™NoYes – L/U
YukonBiologics and BiosimilarsEtanerceptErelzi™NoYes – S/A
British ColumbiaBiologics and BiosimilarsEtanerceptBrenzys®NoYes – S/A
AlbertaBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsEtanerceptBrenzys®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsEtanerceptBrenzys®NoNo
OntarioBiologics and BiosimilarsEtanerceptBrenzys®NoNo
QuebecBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Nova ScotiaBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Prince Edward IslandBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptBrenzys®NoNo
NunavutBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Northwest TerritoriesBiologics and BiosimilarsEtanerceptBrenzys®NoNo
YukonBiologics and BiosimilarsEtanerceptBrenzys®NoYes – S/A

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Etanercept (Enbrel®): https://www.amgen.ca/products/patient-assistance/
Etanercept biosimilar (Erelzi): Call 1-844-27XPOSE (1-844-279-7673) for information

Adalimumab (TNF Blocker)

How Does It Work?

Adalimumab is a biologic that targets the overactive immune system in psoriasis. Adalimumab works by supressing tumor necrosis factor (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Adalimumab is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
80 mg as an initial dose, then 40 mg every other week starting one week after initial dose

For psoriatic arthritis:
40 mg every other week

What Are The Possible Side Effects?

The most common side effects of adalimumab include temporary pain and redness around the injection site, headaches, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of adalimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on adalimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on adalimumab.

Adalimumab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Adalimumab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with adalimumab include abatacept (Orencia®), anakinra (Kineret®) and other TNF-blockers such as Enbrel®, Remicade®, Cimzia®, or Simponi®. Adalimumab can potentially affect the speed at which cyclosporine and warfarin are metabolized and their doses may need to be adjusted. For a complete list of medications that may interact with adalimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHumira®Yes - EDSYes - EDS
ManitobaBiologics and BiosimilarsAdalimumabHumira®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHumira®Yes - L/UNo
QuebecBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. If treatment began before August 19, 2020.Yes - S/A. If treatment began before August 19, 2020.
New BrunswickBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHumira®Yes - EDS Yes - EDS
Prince Edward IslandBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
British ColumbiaBiologics and BiosimilarsAdalimumabHadlima®NoNo
AlbertaBiologics and BiosimilarsAdalimumabHadlima®NoNo
SaskatchewanBiologics and BiosimilarsAdalimumabHadlima®NoNo
ManitobaBiologics and BiosimilarsAdalimumabHadlima®NoNo
OntarioBiologics and BiosimilarsAdalimumabHadlima®NoNo
QuebecBiologics and BiosimilarsAdalimumabHadlima®NoNo
New BrunswickBiologics and BiosimilarsAdalimumabHadlima®NoNo
Nova ScotiaBiologics and BiosimilarsAdalimumabHadlima®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabHadlima®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHadlima®NoNo
NunavutBiologics and BiosimilarsAdalimumabHadlima®NoNo
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHadlima®NoNo
YukonBiologics and BiosimilarsAdalimumabHadlima®NoNo
British ColumbiaBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
AlbertaBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
SaskatchewanBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
ManitobaBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
OntarioBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
QuebecBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
Nova ScotiaBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
NunavutBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
YukonBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
British ColumbiaBiologics and BiosimilarsAdalimumabIdacio®NoNo
AlbertaBiologics and BiosimilarsAdalimumabIdacio®NoNo
SaskatchewanBiologics and BiosimilarsAdalimumabIdacio®NoNo
ManitobaBiologics and BiosimilarsAdalimumabIdacio®NoNo
OntarioBiologics and BiosimilarsAdalimumabIdacio®NoNo
QuebecBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabIdacio®NoNo
Nova ScotiaBiologics and BiosimilarsAdalimumabIdacio®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabIdacio®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabIdacio®NoNo
NunavutBiologics and BiosimilarsAdalimumabIdacio®NoNo
Northwest TerritoriesBiologics and BiosimilarsAdalimumabIdacio®NoNo
YukonBiologics and BiosimilarsAdalimumabIdacio®NoNo
British ColumbiaBiologics and BiosimilarsAdalimumabAmgevita®NoNo
AlbertaBiologics and BiosimilarsAdalimumabAmgevita®NoNo
SaskatchewanBiologics and BiosimilarsAdalimumabAmgevita®NoNo
ManitobaBiologics and BiosimilarsAdalimumabAmgevita®NoNo
OntarioBiologics and BiosimilarsAdalimumabAmgevita®NoNo
QuebecBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabAmgevita®NoNo
Nova ScotiaBiologics and BiosimilarsAdalimumabAmgevita®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabAmgevita®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAmgevita®NoNo
NunavutBiologics and BiosimilarsAdalimumabAmgevita®NoNo
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAmgevita®NoNo
YukonBiologics and BiosimilarsAdalimumabAmgevita®NoNo
British ColumbiaBiologics and BiosimilarsAdalimumabHulio®NoNo
AlbertaBiologics and BiosimilarsAdalimumabHulio®NoNo
SaskatchewanBiologics and BiosimilarsAdalimumabHulio®NoNo
ManitobaBiologics and BiosimilarsAdalimumabHulio®NoNo
OntarioBiologics and BiosimilarsAdalimumabHulio®NoNo
QuebecBiologics and BiosimilarsAdalimumabHulio®Yes – S/A Yes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabHulio®NoNo
Nova ScotiaBiologics and BiosimilarsAdalimumabHulio®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabHulio®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHulio®NoNo
NunavutBiologics and BiosimilarsAdalimumabHulio®NoNo
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHulio®NoNo
YukonBiologics and BiosimilarsAdalimumabHulio®NoNo

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Infliximab (TNF Blocker)

How Does It Work?

Infliximab is a biologic that targets the overactive immune system in psoriasis. Infliximab works by supressing tumor necrosis factor-alpha (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Infliximab is an injectable medication that is administered intravenously, useful for psoriasis and psoriatic arthritis. Typically this is done in an infusion centre.

For plaque psoriasis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter

For psoriatic arthritis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.

What Are The Possible Side Effects?

The most common side effects of infliximab include temporary pain and redness around the infusion site, headaches, nausea, joint pain, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of infliximab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on infliximab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on infliximab.

Infliximab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Infliximab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with infliximab include cyclosporine, echinacea, phenytoin, and warfarin. For a complete list of medications that may interact with infliximab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsInfliximabRemicade®No – S/A. Requests for patients unable to transition to biosimilar infliximab will be considered on an exceptional case-by-case basis.  No – S/A. Requests for patients unable to transition to biosimilar infliximab will be considered on an exceptional case-by-case basis.  
AlbertaBiologics and BiosimilarsInfliximabRemicade®NoNo 
SaskatchewanBiologics and BiosimilarsInfliximabRemicade®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabRemicade®Yes – EDS. Inflectra or Renflexis will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.Yes – EDS. Inflectra or Renflexis will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.
OntarioBiologics and BiosimilarsInfliximabRemicade®No. May be covered through EAP in specific clinical circumstances .No. May be covered through EAP in specific clinical circumstances .
QuebecBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
New BrunswickBiologics and BiosimilarsInfliximabRemicade®Yes. All new S/A requests will be approved for biosimilar versions only. Yes. All new S/A requests will be approved for biosimilar versions only. 
Nova ScotiaBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after December 1, 2016, an infliximab biosimilar will be the product approved. Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after December 1, 2016, an infliximab biosimilar will be the product approved. 
Prince Edward IslandBiologics and BiosimilarsInfliximabRemicade®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; Inflectra or Renflexis are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). No
NunavutBiologics and BiosimilarsInfliximabRemicade®NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemicade®NoNo
YukonBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; all new infliximab patients will be covered for Inflectra brand only.Yes – S/A; all new infliximab patients will be covered for Inflectra brand only.
British ColumbiaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabAvsola®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabAvsola®NoNo
OntarioBiologics and BiosimilarsInfliximabAvsola®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsInfliximabAvsola®NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabAvsola®NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabAvsola®NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabAvsola®NoNo
NunavutBiologics and BiosimilarsInfliximabAvsola®NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabAvsola®NoNo
YukonBiologics and BiosimilarsInfliximabAvsola®NoNo
British ColumbiaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabInflectra®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabInflectra®Yes – EDS Yes – EDS
OntarioBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
British ColumbiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
AlbertaBiologics and BiosimilarsInfliximabOmvyence™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabOmvyence™NoNo
ManitobaBiologics and BiosimilarsInfliximabOmvyence™NoNo
OntarioBiologics and BiosimilarsInfliximabOmvyence™NoNo
QuebecBiologics and BiosimilarsInfliximabOmvyence™NoNo
New BrunswickBiologics and BiosimilarsInfliximabOmvyence™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabOmvyence™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabOmvyence™NoNo
NunavutBiologics and BiosimilarsInfliximabOmvyence™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabOmvyence™NoNo
YukonBiologics and BiosimilarsInfliximabOmvyence™NoNo
British ColumbiaBiologics and BiosimilarsInfliximabRemsima™NoNo
AlbertaBiologics and BiosimilarsInfliximabRemsima™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRemsima™NoNo
ManitobaBiologics and BiosimilarsInfliximabRemsima™NoNo
OntarioBiologics and BiosimilarsInfliximabRemsima™NoNo
QuebecBiologics and BiosimilarsInfliximabRemsima™NoNo
New BrunswickBiologics and BiosimilarsInfliximabRemsima™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabRemsima™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRemsima™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemsima™NoNo
NunavutBiologics and BiosimilarsInfliximabRemsima™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemsima™NoNo
YukonBiologics and BiosimilarsInfliximabRemsima™NoNo
British ColumbiaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabRenflexis®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDS Yes – EDS
OntarioBiologics and BiosimilarsInfliximabRenflexis®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsInfliximabRenflexis®NoNo 
Northwest TerritoriesBiologics and BiosimilarsInfliximabRenflexis®NoNo 
YukonBiologics and BiosimilarsInfliximabRenflexis®NoNo

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Infliximab (Remicade®): https://www.bioadvancemember.ca/en/global/home
Infliximab biosimilar Inflectra®: https://www.pfizer.ca/assistance-programs
Infliximab biosimilar Renflexis®: https://www.merckharmony.ca/

Certolizumab pegol (TNF Blocker)

How Does It Work?

Certolizumab is a biologic that targets the overactive immune system in psoriasis. Certolizumab works by supressing tumor necrosis factor-alpha (TNFa).

Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Certolizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
400 mg every 2 weeks

For psoriatic arthritis:
400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks

What Are The Possible Side Effects?

The most common side effects of certolizumab include joint pain, and an increased risk of  upper respiratory tract infections and urinary tract infections. To obtain a comprehensive list of all known potential side effects of certolizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on certolizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on certolizumab.

Certolizumab should be avoided in patients with moderate to severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with certolizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with certolizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
AlbertaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
SaskatchewanBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
ManitobaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
OntarioBiologics and BiosimilarsCertolizumab pegol Cimzia®No – may be covered through EAP in specific clinical circumstancesNo – may be covered through EAP in specific clinical circumstances 
QuebecBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
New BrunswickBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
Nova ScotiaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
NunavutBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – L/U
YukonBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Golimumab (TNF Blocker)

How Does It Work?

Golimumab is a biologic that targets the overactive immune system in psoriatic arthritis. Golimumab works by supressing tumor necrosis factor-alpha (TNFa).

How Is It Used?

Golimumab is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of golimumab are an increased risk of infection and a temporary injection site reaction. To obtain a comprehensive list of all known potential side effects of golimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on golimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on golimumab.

Golimumab should be avoided in patients with severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with golimumab include abatacept, anakinra, baricitinib, belimumab, canakizumab, certolizumab pegol, cladribine, echinacea, infliximab, leflunomide, natalizumab, pimecrolimus, rilonacept, roflumilast, tacrolimus, tocilizumab, tofacitinib, and vedolizumab. For a complete list of medications that may interact with golimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
AlbertaBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
SaskatchewanBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
ManitobaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
OntarioBiologics and BiosimilarsGolimumabSimponi®No – EAP may cover in specific clinical circumstances.No – EAP may cover in specific clinical circumstances. 
QuebecBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
New BrunswickBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
Nova ScotiaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
NunavutBiologics and BiosimilarsGolimumabSimponi®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsGolimumabSimponi®NoYes – L/U
YukonBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Ixekizumab (IL17 Blocker)

How Does It Work?

Ixekizumab is a biologic that targets the overactive immune system in psoriasis. Ixekizumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ixekizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks

For psoriatic arthritis:
160 mg once, followed by 80 mg every 4 weeks

What Are The Possible Side Effects?

The most common side effects of ixekizumab include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ixekizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ixekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ixekizumab.

Ixekizumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ixekizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ixekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/A Yes – S/A
AlbertaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UNo 
QuebecBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsIxekizumabTaltz®NoNo

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Call 1-877-219-8908 for information.

Brodalumab (IL17 Blocker)

How Does It Work?

Brodalumab is a biologic that targets the overactive immune system in psoriasis. Brodalumab works by preventing interleukin-17 from causing inflammation.

How Is It Used?

Brodalumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks

What Are The Possible Side Effects?

The most common side effect of brodalumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of brodalumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on brodalumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on brodalumab.

Brodalumab should be avoided in patients with Crohn’s disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with brodalumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with brodalumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsBrodalumabSiliq™NoNo
AlbertaBiologics and BiosimilarsBrodalumabSiliq™NoNo
SaskatchewanBiologics and BiosimilarsBrodalumabSiliq™Yes – EDS No
ManitobaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSNo
OntarioBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UNo
QuebecBiologics and BiosimilarsBrodalumabSiliq™Yes – S/ANo
New BrunswickBiologics and BiosimilarsBrodalumabSiliq™Yes – S/ANo
Nova ScotiaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSNo
Prince Edward IslandBiologics and BiosimilarsBrodalumabSiliq™Yes – S/ANo
Newfoundland and LabradorBiologics and BiosimilarsBrodalumabSiliq™Yes – S/ANo
NunavutBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UNo
Northwest TerritoriesBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UNo
YukonBiologics and BiosimilarsBrodalumabSiliq™NoNo

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Call 1-844-852-6967 for information.

Secukinumab (IL17 Blocker)

How Does It Work?

Secukinumab is a biologic that targets the overactive immune system in psoriasis. Secukinumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Secukinumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks

For psoriatic arthritis:
For patients not treated previously by a biological agent – 150 mg (or 300 mg for some patients) once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks. For those with previous treatment with a biologic agent – 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.

What Are The Possible Side Effects?

The most common side effect of secukinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of secukinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on secukinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on secukinumab.

Secukinumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with secukinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with secukinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UNo 
QuebecBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDS Yes – EDS
Prince Edward IslandBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Ustekinumab (IL12/23 Blocker)

How Does It Work?

Ustekinumab is a biologic that targets the overactive immune system in psoriasis. Ustekinumab works by suppressing interleukin 12 and interleukin 23. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ustekinumab is an injectable medication that is administered subcutaneously. Can be home dosed.

For plaque psoriasis:
≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter
>100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter

For psoriatic arthritis:
45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

What Are The Possible Side Effects?

The most common side effect of ustekinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ustekinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ustekinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ustekinumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ustekinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ustekinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
AlbertaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
SaskatchewanBiologics and BiosimilarsUstekinumabStelara®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsUstekinumabStelara®Yes – EDS No
OntarioBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
QuebecBiologics and BiosimilarsUstekinumabStelara®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Nova ScotiaBiologics and BiosimilarsUstekinumabStelara®Yes – EDSNo
Prince Edward IslandBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
NunavutBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Northwest TerritoriesBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
YukonBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Risankizumab (IL23 Blocker)

How Does It Work?

Risankizumab is a biologic that targets the overactive immune system in psoriasis. Risankizumab works by supressing interleukin-23A.

How Is It Used?

The recommended dose of SKYRIZI is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter. 

What Are The Possible Side Effects?

The most common side effect of risankizumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of risankizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on risankizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on risankizumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

N/A

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/ANo
AlbertaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/ANo
SaskatchewanBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSNo
ManitobaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSNo
OntarioBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UNo
QuebecBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/ANo
New BrunswickBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/ANo
Nova ScotiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDS No
Prince Edward IslandBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/A No
Newfoundland and LabradorBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/ANo
NunavutBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UNo
Northwest TerritoriesBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UNo
YukonBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/ANo

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Guselkumab (IL23 Blocker)

How Does It Work?

Guselkumab is a biologic that targets the overactive immune system in psoriasis. Guselkumab works by neutralizing interleukin-23.

How Is It Used?

Guselkumab is an injectable medication that is administered subcutaneously by injection. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.

For plaque psoriasis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

For psoriatic arthritis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

The most common side effect of guselkumab is an increased risk of respiratory tract infections. To obtain a comprehensive list of all known potential side effects of guselkumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on guselkumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on guselkumab.

Patients should be screened for tuberculosis and infections prior to treatment.

Do not use TREMFYA®/TREMFYA One-Press™ if you are allergic to guselkumab or any of the ingredients in TREMFYA®/TREMFYA OnePress™.

If you think you are allergic, ask your healthcare professional for advice before using TREMFYA®/TREMFYA One-Press™.

 

What Medications Interact With This Treatment?

For a complete list of medications that may interact with guselkumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

 

 

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
AlbertaBiologics and BiosimilarsGuselkumabTremfya®NoNo
SaskatchewanBiologics and BiosimilarsGuselkumabTremfya®NoNo
ManitobaBiologics and BiosimilarsGuselkumabTremfya®NoNo
OntarioBiologics and BiosimilarsGuselkumabTremfya®NoNo
QuebecBiologics and BiosimilarsGuselkumabTremfya®NoNo
New BrunswickBiologics and BiosimilarsGuselkumabTremfya®NoNo
Nova ScotiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
Prince Edward IslandBiologics and BiosimilarsGuselkumabTremfya®NoNo
Newfoundland and LabradorBiologics and BiosimilarsGuselkumabTremfya®NoNo
NunavutBiologics and BiosimilarsGuselkumabTremfya®NoNo
Northwest TerritoriesBiologics and BiosimilarsGuselkumabTremfya®NoNo
YukonBiologics and BiosimilarsGuselkumabTremfya®NoNo

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Health Canada Product Monograph
https://pdf.hres.ca/dpd_pm/00057930.PDF

Abatacept

How Does It Work?

Abatacept is a biologic that targets the overactive immune system in psoriatic arthritis. Abatacept works by supressing the activation of white blood cells called T-cells.

How Is It Used?

Abatacept is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of abatacept are headache, nausea, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of abatacept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on abatacept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on abatacept.

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of experience COPD-related adverse events such as cough, shortness of breath, and infection while on abatacept.

Abatacept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with abatacept include anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, baricitinib, belimumab, cladribine, echinacea, leflunomide, natalizumab, pimecrolimus, rituximab, roflumilast, tacrolimus, tocilizumab, and tofacitinib. For a complete list of medications that may interact with abatacept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsAbataceptOrencia®NoNo
AlbertaBiologics and BiosimilarsAbataceptOrencia®NoNo
SaskatchewanBiologics and BiosimilarsAbataceptOrencia®NoNo
ManitobaBiologics and BiosimilarsAbataceptOrencia®NoNo
OntarioBiologics and BiosimilarsAbataceptOrencia®No. EAP may cover in specific clinical circumstances. No. EAP may cover in specific clinical circumstances. 
QuebecBiologics and BiosimilarsAbataceptOrencia®NoNo
New BrunswickBiologics and BiosimilarsAbataceptOrencia®NoNo
Nova ScotiaBiologics and BiosimilarsAbataceptOrencia®NoNo
Prince Edward IslandBiologics and BiosimilarsAbataceptOrencia®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAbataceptOrencia®NoNo
NunavutBiologics and BiosimilarsAbataceptOrencia®NoNo
Northwest TerritoriesBiologics and BiosimilarsAbataceptOrencia®NoNo
YukonBiologics and BiosimilarsAbataceptOrencia®NoNo

 

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

This site is updated regularly; however this is information is subject to change.  For the most up-to-date information regarding your specific province / territory click here.

Last updated July 24, 2020.

Disclaimer

This Site was designed for educational purposes only and not for the purpose of rendering medical advice. Individual variances in psoriasis cases require the consultation of a physician to make sound medical decisions. The information presented on this website is not intended to replace the counsel of your physician. It is important to see your doctor before altering anything in your treatment plan. The Canadian Psoriasis Network does not endorse any medications, products, equipment or treatments for psoriasis and psoriatic arthritis. Any of the information contained within the Canadian Psoriasis Network’s Site is not presented as a substitute for informed medical advice. Visitors to this site should not engage in self-diagnosis nor act on information contained in the Site without seeking specific advice on the particular matters which are of concern to them from qualified health professionals and advisors. Some of the information contained in the Site has been provided from external sources. While efforts have been made to ensure the accuracy, currency, and reliability of the content, the Canadian Psoriasis Network accepts no responsibility in that regard. Please refer to our Terms of Use for further details.

This resource was made possible through support from:

Abbvie
Pfizer
Janssen
Bausch
 
LEO Pharma
Novartis
Amgen